To any new readers today: congratulations on having found this incredibly undervalued stock. We have 3 very different drugs in clinical trials, all of which have been successful thus far. Our antibiotic/anti-inflammatory, Brilacidin, is in clinical trials for multiple different applications -- for starters, the Ulcerative Proctitis version, whose clinical trial results were reported yesterday; the Oral Mucositis formulation, whose preliminary results look extremely promising (and for which there is no effective treatment as yet); Prurisol for psoriasis (and potentially other applications); and Kevetrin, the drug that seemingly turns on the body's on anti-cancer mechanism which some cancers turn off when they proliferate.

Every clinical trial thus far, for all these drugs in their various applications, has been successful. Yesterday's Brilacidin-UP results were nothing short of phenomenal -- achieving remission for many after only 6 weeks of treatment.